AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 4, 2026 Revolution Medicines reported RASONQUE net product revenue of $197.6 million for the quarter ended September 30, 2026. AI-generated summary · Source: company release
NASDAQ: $RVMDBiotech · RAS-targeted oncologyLaunch trajectory, trial and financing risk

RVMD Stock Hub: Revolution Medicines News, RASONQUE and RAS Trials

RASONQUE was approved and launched in the U.S. in August 2026. Q3 product revenue of $197.559M reflects approximately five launch weeks, initial stocking and finite early patient transitions. September cash and securities were $3,651.385M; the European Commission decision remained pending after the positive CHMP opinion. Q3 2026 Form 10-Q · November 4 Q3 results and commercial update · November 4, 2026 EMA Rasonque positive CHMP opinion · October 15, 2026

Last updated: November 12, 2026Market data: November 11, 2026 regular closeFinancial period: September 30, 2026Currency: USD
Research Library · Biotech
Revolution Medicines: RASONQUE Launch and the RAS Development Franchise
Initial pancreatic-cancer launch, global development and the cost of expansion · November 12, 2026
Get the report (PDF)
Next catalyst · Announced investor presentation
November 16, 2026 · Jefferies Global Healthcare Conference, London

The company scheduled a fireside chat for 05:30 New York / 10:30 London. This is a corporate presentation, with no specific new clinical dataset promised. The November 10 Guggenheim event and November 4 results call have passed. November investor conferences · October 27, 2026

The latest commercial update was November 4. RASolve 301 enrollment was expected to close across sites by the end of November, with an initial readout anticipated in 2027. Q3 results and commercial update · November 4, 2026
RVMD daily price chart
Daily chart · Finviz (affiliate link on click). Explore RVMD on JC Just Charts.

RVMD stock data: financial position and capital

Regular close
$180.70
November 11, 2026 · completed regular session
Common-stock value
$39.084B
Calculated: $180.70 × 216,292,323 October 30 shares
Cash and securities
$3,651.385M
September 30, 2026 · restricted cash excluded
Q3 product revenue
$197.559M
Partial launch quarter · net RASONQUE sales
Q3 net loss
$(407.457)M
Includes $40.702M non-cash warrant remeasurement
Nine-month operating cash use
$1,157.134M
January–September 2026
2026 operating expense guidance
$2.1B–$2.2B
November 4 outlook · includes $270M–$290M stock compensation
October term-loan principal
$250M
Received after September close · $5M upfront fee

The share count and price have different dates. September resources exclude restricted cash of $15.830M and the $250M term-loan principal received in October, which carried a $5M upfront fee. Further funding capacity is conditional and is not current cash. Q3 2026 Form 10-Q · November 4 Q3 results and commercial update · November 4, 2026

RASONQUE launch: early demand meets a broad development bill

Early launch revenue includes EAP transitions, patients awaiting approval and initial channel stocking. The $0.327M cost of sales also benefits from manufacturing costs expensed before approval. Neither figure establishes normalized revenue or gross margin. Q3 results and commercial update · November 4, 2026 Q3 2026 Form 10-Q · November 4

▲ The constructive case

U.S. approval supplies a commercial base and a randomized survival result in metastatic pancreatic cancer. Wider access and successful first-line or lung-cancer studies could expand the franchise. The large reported resource balance supports simultaneous development and commercialization. FDA daraxonrasib approval · August 26, 2026 Q3 results and commercial update · November 4, 2026

▼ The cautious case

The launch trajectory is still forming, while broader development requires substantial spending. Other indications and combinations remain investigational. Royalty rights, debt, convertible notes and employee awards affect retained value, and commercial execution remains concentrated in one approved medicine. Q3 2026 Form 10-Q · November 4 Q3 results and commercial update · November 4, 2026

Latest RVMD news

Nov 4, 2026

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

Revolution Medicines reported financial results for the quarter ended September 30, 2026, and an update on corporate progress. The U.S. Food and Drug Administration approved RASONQUE (daraxonrasib) on August 26, 2026, and RASONQUE generated net product revenue of $197.6 million for the quarter. From FDA approval through September 30, 2026, more than 5,000 unique patients received commercial RASONQUE in the U.S. The company also received a positive CHMP opinion recommending marketing authorization of daraxonrasib in the European Union.

Company release · SEC

RVMD stock catalysts: launch follow-through and controlled trial milestones

Registry primary-completion dates concern study operations and are not promised public readout dates. The 2026 U.S. approval and October CHMP opinion are completed events. RASONQUE remains investigational outside its approved U.S. indication. FDA daraxonrasib approval · August 26, 2026 EMA Rasonque positive CHMP opinion · October 15, 2026 Q3 2026 Form 10-Q · November 4

RASONQUE business and clinical evidence

Revolution Medicines develops oral RAS(ON) inhibitors from its tri-complex platform. Daraxonrasib is multi-selective; zoldonrasib targets G12D, elironrasib G12C and RMC-5127 G12V. RASONQUE is the marketed daraxonrasib brand, approved only for its specified U.S. metastatic pancreatic-cancer indication. Q3 2026 Form 10-Q · November 4 FDA daraxonrasib approval · August 26, 2026

RASolute 302 randomized 500 previously treated metastatic-PDAC patients. In the overall population, median OS was 13.2 versus 6.7 months, HR 0.40; median PFS was 7.2 versus 3.6 months, HR 0.49. Serious adverse reactions occurred in 30% of treated RASONQUE patients. First-line combinations, adjuvant disease and NSCLC require separate evidence and approvals. FDA daraxonrasib approval · August 26, 2026 RASONQUE U.S. prescribing information · August 2026

RVMD earnings, capital and retained economics

September cash and securities were $3,651.385M; nine-month operating cash use was $1,157.134M. Q3 net product sales were $197.559M, R&D $417.087M and SG&A $153.294M. The October $250M debt principal is a subsequent event; it is not included in September cash. Q3 2026 Form 10-Q · November 4

September common shares were 216,251,663, with 17,699,003 options and 4,825,674 unvested RSUs. The EPS note also lists shares issuable under notes and warrants. Royalty Pharma has rights to specified future sales; additional optional funding can change those economics. Q3 2026 Form 10-Q · November 4

Merlintrader Health Score · RVMD

3.95out of 5
Financial position4.0

September 30 cash and securities were $3,651.385M; nine-month operating cash use was $1,157.134M. October debt and conditional further funding are separate. Q3 2026 Form 10-Q · November 4

Catalysts4.5

U.S. approval and launch are completed. Jefferies is scheduled November 16, RASolve 301 enrollment closure is targeted for end-November and initial readout for 2027. EU authorization remains pending. Q3 results and commercial update · November 4, 2026 EMA Rasonque positive CHMP opinion · October 15, 2026 November investor conferences · October 27, 2026

Dilution3.0

Employee awards, convertible notes, warrants and ATM capacity remain relevant alongside synthetic royalties and debt. The April common offering increased shares outstanding. Q3 2026 Form 10-Q · November 4

Trading liquidity4.0

RVMD trades on Nasdaq Global Select Market. The latest cover count was 216,292,323 common shares as of October 30. Regulatory, clinical and launch news can still produce price gaps. Q3 2026 Form 10-Q · November 4

Execution4.0

RASONQUE generated $197.559M in initial Q3 net sales after approval, supported by randomized survival evidence. Launch normalization, international access and broader trials remain open execution requirements. FDA daraxonrasib approval · August 26, 2026 Q3 2026 Form 10-Q · November 4 Q3 results and commercial update · November 4, 2026

Weighted calculation: 4.0 × 30% + 4.5 × 30% + 3.0 × 20% + 4.0 × 10% + 4.0 × 10% = 3.95 out of 5. Editorial assessment dated November 12, 2026. Weights: financial position 30%, catalysts 30%, dilution 20%, trading liquidity 10%, execution 10%. Not an investment recommendation or probability of approval.

RVMD red flags

RVMD Stock FAQ: Revolution Medicines Questions Answered

What is the next RVMD stock catalyst for Revolution Medicines?

As of November 12, 2026, the next announced investor event was Jefferies in London on November 16 at 05:30 New York / 10:30 London. The company also targeted RASolve 301 enrollment closure by end-November and an initial readout in 2027. November investor conferences · October 27, 2026 Q3 results and commercial update · November 4, 2026

Is RVMD RASONQUE FDA-approved, and what is its European status?

On August 26, 2026, FDA approved RASONQUE for adults with metastatic pancreatic adenocarcinoma who received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Other indications and combinations remain investigational; the pending European Commission decision is distinct from an FDA PDUFA date. FDA daraxonrasib approval · August 26, 2026 EMA Rasonque positive CHMP opinion · October 15, 2026

How much cash does Revolution Medicines have for RVMD development?

At September 30, 2026, cash, equivalents and marketable securities totaled $3,651.385M, excluding $15.830M restricted cash. October brought $250M term-loan principal with a $5M upfront fee. The further $1B funding capacity depends on milestones and company elections; it is not cash already received. Q3 2026 Form 10-Q · November 4 Q3 results and commercial update · November 4, 2026

What are the main RVMD share dilution risks?

At September 30, 2026, Revolution Medicines had 216,251,663 common shares, 17,699,003 options and 4,825,674 unvested RSUs. Convertible notes and warrants create additional potential share exposure. The new $1B ATM replaced the older program; future sales depend on actual issuance. Q3 2026 Form 10-Q · November 4

What were the latest Revolution Medicines earnings for RVMD?

For Q3 ended September 30, 2026, Revolution Medicines reported $197.559M net product revenue, $417.087M R&D, $153.294M SG&A and a $407.457M net loss. The November 4 release cautioned that early launch revenue and cost of sales do not establish a normalized commercial trajectory. Q3 2026 Form 10-Q · November 4 Q3 results and commercial update · November 4, 2026

What does Revolution Medicines do for RVMD holders?

As of November 12, 2026, Revolution Medicines develops and commercializes RAS-targeted oncology medicines. RASONQUE is approved in its specified U.S. metastatic pancreatic-cancer population. The broader portfolio includes daraxonrasib expansion studies, G12D-selective zoldonrasib, G12C-selective elironrasib and earlier RAS(ON) programs. Q3 2026 Form 10-Q · November 4 FDA daraxonrasib approval · August 26, 2026

Why is the initial RASONQUE launch unusual for RVMD?

In Q3 2026, about five weeks of commercial sales included expanded-access transitions, an initial group awaiting treatment and channel stocking. Some product manufacturing costs had already been expensed before approval. Those finite factors affect interpretation of both revenue and the exceptionally low reported cost of sales. Q3 results and commercial update · November 4, 2026 Q3 2026 Form 10-Q · November 4

What did RASolute 302 show for RVMD RASONQUE?

At the February 10, 2026 cutoff, the 500-patient randomized trial showed median overall survival of 13.2 versus 6.7 months in the overall population, HR 0.40. Median PFS was 7.2 versus 3.6 months, HR 0.49. The approved label also describes significant adverse reactions and warnings. FDA daraxonrasib approval · August 26, 2026 Corporate presentation · November 4, 2026 RASONQUE U.S. prescribing information · August 2026

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $RVMD or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data or decline to file an application, and companies that spend ahead of revenue raise equity at whatever price the market will bear. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate. Investors may lose part or all of their capital.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.

Trending now

Bright illustration of blood cells, medicines and molecular structures for hereditary angioedema research.
BioCryst $BCRX $IONS $TAK $NTLA: HAE Treatment Choices
Colorful minerals and processing infrastructure illustrating rare-earth co-product economics.
Ramaco $METC $AREC $NB $UUUU: Rare Earth Economics
Colorful semiconductor memory stack and inspection equipment illustrating the AI memory supply chain.
Micron $MU, $RMBS, $AMKR, $CAMT: AI Memory Economics
LNG carrier, onshore facility and floating liquefaction vessel in a sunlit coastal scene.
Cheniere $LNG $VG $NEXT $GLNG: Four LNG Business Models